Relfydess recieves for glabellar lines in China
Pharmaceutical company Galderma has announced that China’s National Medical Products Administration (NPA) has approved Relfydess (relabotulinumtoxinA) for the temporary improvement of moderate-to-severe glabellar lines in adults. The approval is supported